Antipsychotics in children: an overview

Prescribing an antipsychotic to a child is one of the more weighted decisions in psychiatry. The medications can be life-changing for a young person whose psychotic illness is otherwise unmanageable. They also carry side effects that hit children harder than adults — particularly weight gain, metabolic shifts, and prolactin elevations. This overview is for parents, caregivers, and young patients trying to understand what is on the table and what questions to ask.

What the FDA has approved for children

The FDA pediatric labeling program has formally extended several antipsychotic indications to younger patients. The labels — and the ages they cover — are publicly available in the manufacturer prescribing information. In broad strokes:

• Schizophrenia in adolescents (typically 13–17): aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, lurasidone
• Bipolar I manic or mixed episodes (typically 10–17): aripiprazole, asenapine, olanzapine, quetiapine, risperidone
• Bipolar depression in adolescents: lurasidone, olanzapine-fluoxetine combination
• Irritability associated with autism (5–17 or 6–17): aripiprazole, risperidone
• Tourette's disorder: aripiprazole, haloperidol, pimozide

Off-label use also occurs — for severe aggression, treatment-resistant ADHD with explosive outbursts, or other conditions — and a 2023 AACAP practice guidance emphasizes that off-label use should be considered only after first-line treatments have failed and with explicit informed consent.

Why children are not just small adults on these drugs

Three things make pediatric prescribing different:

• Weight gain is more pronounced. Studies of risperidone, olanzapine, and quetiapine in children consistently show greater absolute and percentage weight gain than in adults — sometimes 5–10 kg in the first 6 months on olanzapine.
• Metabolic changes are sharper. Insulin resistance, lipid changes, and prolactin elevations can develop within weeks. The American Academy of Child and Adolescent Psychiatry recommends baseline and ongoing metabolic monitoring on a stricter schedule than for adults.
• Sedation interferes with school. A medication that simply makes an adult tired at work can make a child unable to attend or function at school.

What good monitoring looks like

For any child started on an antipsychotic, the AACAP and APA jointly recommend:

• Baseline weight, height, BMI percentile, waist circumference, blood pressure
• Baseline fasting glucose, HbA1c, lipid panel
• Baseline prolactin in children with risk factors or starting risperidone/paliperidone
• ECG when using ziprasidone, pimozide, haloperidol, or other QT-prolonging agents
• Repeat metabolic labs at 3 months and at least every 6 months thereafter
• AIMS (Abnormal Involuntary Movement Scale) at baseline and every 6 months — see our tardive dyskinesia article

How prescribers think about the decision

For most child and adolescent psychiatrists, the decision tree looks like this:

1. Is the diagnosis clear? Childhood-onset schizophrenia, bipolar I with mania, severe autism-related irritability with safety concerns — these are settings where antipsychotics have a clear evidence base.
2. Have non-medication interventions been tried? Behavioral therapy, family therapy, school accommodations, sleep stabilization. For autism-related irritability, applied behavior analysis and parent training are usually first.
3. What is the goal of treatment? Symptom reduction, safety, school functioning. The goal shapes which agent and which dose.
4. Which agent has the best risk-benefit profile for this child? Considering weight, metabolic risks, sedation, prolactin effects, and the child's other medical conditions.
5. What is the plan to monitor and de-escalate? Many pediatric prescribers plan a re-evaluation at 6 and 12 months to see if the medication can be reduced or discontinued.

What parents tend to worry about

"Will this change my child's personality?"

Antipsychotics treat symptoms — voices, paranoia, mania, severe aggression. They do not erase a personality. Many families describe their child as "more themselves" once the symptoms are controlled. Over-sedation is a real possibility and should be reported promptly so the dose or agent can be adjusted.

"Will my child be on this forever?"

Not necessarily. For some conditions — particularly schizophrenia — long-term treatment is the norm. For others, like autism-related irritability or some bipolar presentations, courses can be time-limited and reviewed at regular intervals.

"What about brain development?"

This is one of the most common parental concerns. The honest answer is that long-term studies of antipsychotic effects on the developing brain are still maturing. The current consensus from NIMH and AACAP is that, when an antipsychotic is genuinely indicated, the risks of untreated severe psychiatric illness in childhood — including persistent psychosis, developmental delays, and self-harm — outweigh the medication risks. The reasoning is harder when the indication is borderline.

Side effects that need urgent attention

Practical questions to ask your prescriber

• What is the specific diagnosis you are treating?
• Why this medication rather than another?
• What is the target dose and how long until we know if it is working?
• What baseline labs will we do, and what will the monitoring schedule look like?
• What signs should we call you about, and which warrant the emergency department?
• When will we re-evaluate whether the medication is still needed?

The big picture

Antipsychotics in children are a genuine option — sometimes the right one — for serious psychiatric illness. They are not a casual choice, and they are not appropriate for the kind of mild oppositionality or anxiety that should be addressed with therapy and family support first. When they are indicated, the combination of a clear diagnosis, the lowest effective dose, careful monitoring, and a plan for review gives the best chance of helping a child without producing avoidable harm.

For related reading, see teens and antipsychotics, childhood-onset schizophrenia, and very early-onset schizophrenia.

This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.